Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus CCFM1130
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus CCFM1130 is a specific probiotic strain developed by Jiangnan University, primarily recognized for its therapeutic potential in heavy metal detoxification and chronic metabolic disorders. The strain is characterized by its high capacity to bind and sequester lead (Pb) ions within the gastrointestinal tract, thereby reducing systemic absorption and promoting fecal excretion. Beyond its role in lead poisoning, CCFM1130 has been extensively researched for its ability to modulate the gut-kidney axis. In the context of chronic kidney disease (CKD), it helps reduce the accumulation of uremic toxins, such as p-cresol sulfate, by altering the gut microbiota composition and preserving intestinal barrier integrity. Additionally, the strain exhibits antioxidant properties and has shown potential in managing hyperuricemia by regulating uric acid metabolism and excretion.
- Other names
- Lacticaseibacillus rhamnosus CCFM1130鼠李糖乳杆菌CCFM1130
Beyond the preview
Go deeper on lactobacillus rhamnosus CCFM1130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus CCFM1130.